An observational study in Brain Development Abnormality and Sickle Cell Disease, sponsored by Dr. Marjon H. Cnossen MD PhD. Recruiting at 2 sites in Netherlands. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2022-10-04.
Sponsored by Dr. Marjon H. Cnossen MD PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Anemia, Sickle Cell with a site in Netherlands — 7 open to participants now, 12 under way, 4 of them phase 3. Anemia, Sickle Cell · Netherlands.
Among the 30 studies in Anemia, Sickle Cell with a site in Netherlands, this one is one of 7 that started in 2022, is one of 9 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 19th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →7 of the 30 studies in Anemia, Sickle Cell with a site in Netherlands are open now. Recruiting first, the newest first:
CSL Behring · Sites in Netherlands, United States, Belgium and 4 more countries
Ages 18+
Sanofi · Sites in Netherlands, United States, Belgium and 11 more countries
Ages 10–65
Novo Nordisk A/S · Sites in Netherlands, United States, Australia and 18 more countries
Ages 12+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 6–18
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 16+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 6 Years to 25 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 8
First in 2005; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 95 across the 21 interventional studies, 84 across the 9 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 30 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Marjon H. Cnossen MD PhD as lead sponsor.
Dr. Marjon H. Cnossen MD PhD has 1 study filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
3 of the studies in Anemia, Sickle Cell with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06975865Phase 3SanofiThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | 2027-07-23 |
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT06794281Hospital Universitari Vall d'Hebron Research InstituteSynthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case | 2026-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Anemia, Sickle Cell with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sickle cell disease (SCD) is an autosomal recessive red blood cell blood disorder. One especially vital organ affected in SCD is the brain. Individuals with SCD have an increased risk of both overt cerebral infarctions and silent infarctions. The latter are brain lesions without apparent neurological sequelae. Since cortical neurons in the brain lack the ability to regenerate, tissue damage accumulates throughout the already shortened lifespan of individuals with SCD, resulting in far-reaching consequences such as significant cognitive impairment. Currently, only hematological stem cell transplantation can halt the multiorgan tissue damage. However, the criteria to determine the timing of curative therapy do not center the brain, despite that subtle anomalies of this critical organ can have long-lasting consequences. Since it is not yet known whether brain tissue damage precedes, parallels, or lags behind non-brain tissue damage, it is critical to map these effects in youth with SCD. While importantly comparing images with a healthy reference population. Understanding how the brain is affected is critical for clinical decision making, such as timing of potentially curative interventions but also, to prevent long term irreversible brain damage in youth with SCD. In this study, a cohort of 84 SCD patients between the ages of 6 and 18 at baseline, will undergo MR imaging, neurological examination, neuropsychological assessment and blood sampling three times in total, with intervals of two years; results will be innovatively compared with children included in the Generation R population study (±8000 MRIs children and (young)adults) 6-20 years of age). Our hypothesis, based on the inability of the brain to generate new cortical neurons following cell death, is that brain function is impaired earlier than other organ systems and that there is an age-dependent limit in the brain's ability to remodel itself based on neuroplasticity.
Objective: The primary objective is to evaluate longitudinal developmental changes in brain structure in patients aged 6-18 years with SCD. The secondary objective is to analyze the longitudinal relations between biomarkers, demographic characteristics, brain structure, neurocognitive functioning, behavioral functioning and developmental changes in brain structure.
Study Design: Longitudinal cohort study (BRICK) with a duration of 4 years. Study population: Children and adolescents with sickle cell disease (SCD) of all genotypes (e.g. HbSS, HbSβº, HbSβ+, and HbSC) aged 6 -18 years. This will be compared to a cohort of healthy children and adolescents from Generation R.
Primary study endpoint:
Children and adolescents diagnosed with SCD of all genotypes, treated at Erasmus MC and the Amsterdam UMC, ranging from 6 to 18 years at initiation of the study.
The clinical phenotype of SCD consists of a spectrum: From the patients with a high hemoglobin plus an absent or lower incidence of VOCs to the patients with a higher hemoglobin and a higher incidence of VOCs. We chose to include SCD patients of all genotypes, not only the HbSS and Hbẞ0 thalassemia, to cover the whole phenotypic range of SCD. This was chosen in order to infer the possible causes of an expected difference in white matter volume increase, like anemia and sickling-propensity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Parents/ guardians (in case of minors) or patients themselves (>16 years) unable to make an informed decision on participating in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children between 6 and 18 years of age of genotypes HbSS, HbSβº
Diagnostic Test: MR scan of the brain · Diagnostic Test: Blood work · Diagnostic Test: Neurological examination · Diagnostic Test: Neuropsychological assessment
Children between 6 and 18 years of age of genotypes HbSβ+, and HbSC and more
Diagnostic Test: MR scan of the brain · Diagnostic Test: Blood work · Diagnostic Test: Neurological examination · Diagnostic Test: Neuropsychological assessment
Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
Lab work for current lab values and biobanking
Classical neurological examination
Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults * Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA) * A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II) * Narrative memory * Word fluency * Route finding NEPSY-II * World Fluency * Additional Questionnaires (6-18 years): * Child Behavior Checklist (CBCL) * Teacher Report Form (TRF) * Youth Self Report (YSR) * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report) * Conners-3® • Additional Questionnaires (18+ years): * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70) * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70) * Conners' Adult ADHD Rating Scales (CAARS) Emma toolbox
mm3/time unit
Total white matter volume increase in children and adolescents with SCD
Time frame: 4 years
Full scale IQ (FSIQ)
Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization)
Time frame: 4 years
Incidence of stroke
Time frame: 4 years
Other forms complications due to SCD
Time frame: 4 years
Amount of hospital admissions
Time frame: 4 years
Ld, bilirubin
Hemolysis biomarkers
Time frame: 4 years
Times/year
ER visits
Time frame: 4 years
Hb, Ht
Biomarkers for anemia
Time frame: 4 years
T score metric: a score of 50 represents the mean score of a reference population and 10 is the standard deviation.
Patient-Reported Outcomes Measurement Information System® (PROMIS) within domains such as fatigue, pain behavior, depression, anxiety
Time frame: 4 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jul 2025, 36 months after the start.
Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 36 months is below that.
Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.